Written and maintained by CASRAI Editorial Board
Last updated
Quick answer: FDA can require a Risk Evaluation and Mitigation Strategy (REMS) for a drug or biologic — at approval or after a drug is already on the market — whenever it determines a REMS is necessary to ensure the drug’s benefits outweigh its risks. That determination isn’t discretionary guesswork: the statute (21 U.S.C. § 355-1(a)(1), added by the FDA Amendments Act of 2007) requires FDA to weigh six specific factors before it can impose one. Whether that REMS then includes the most restrictive tier — Elements to Assure Safe Use (ETASU) — is a second, separate decision, not an automatic upgrade. This guide walks through both decisions and what they mean operationally for a research site or manufacturer.
The Six Factors FDA Must Weigh Before Requiring a REMS
Under 21 U.S.C. § 355-1(a)(1), before FDA can require a REMS at the time of approval, it must consider all six of these factors together — no single factor is dispositive on its own:
| Statutory factor | What FDA is actually asking |
|---|---|
| Estimated population size | How many patients are likely to use the drug — a wider exposure raises the stakes of an unmanaged risk. |
| Seriousness of the disease/condition | Is the underlying condition itself severe enough that added friction to access is still justified? |
| Expected benefit of the drug | How much clinical benefit does the drug offer relative to that condition? |
| Expected/actual duration of treatment | A short course carries different cumulative risk than chronic, indefinite use. |
| Seriousness of known/potential adverse events | Including their background incidence in the population likely to use the drug — how bad, and how often, absent controls? |
| Whether the drug is a new molecular entity | A novel compound has a thinner real-world safety record than a reformulation of an established drug. |
These same six factors apply whether FDA is requiring a REMS as a condition of initial approval (21 U.S.C. § 355-1(a)(1)) or imposing one later on an already-marketed drug after new safety information emerges (21 U.S.C. § 355-1(a)(2)) — a manufacturer has 120 days to submit a proposed strategy once FDA notifies it of that postapproval determination, or less if FDA requires a faster timeline to protect public health.
When Is a REMS Required? Initial Approval vs. Postapproval
- At initial approval — FDA’s review divisions (in consultation with the office responsible for postapproval drug safety) make the determination as part of reviewing the marketing application, before the drug ever reaches the market. This is the more common path: risk is identified in clinical trial data before approval.
- Postapproval — FDA can require a REMS on a drug that was approved without one if it later becomes aware of new safety information: a signal from a postmarket study, an adverse-event report pattern, or peer-reviewed literature. This is how a drug that has been marketed under ordinary labeling for years can suddenly need a REMS — the trigger is new evidence, not a change in the underlying law.
In both cases, the determination must be made by an individual at or above the level authorized to approve a drug (for example, a division director within FDA’s Center for Drug Evaluation and Research) — it isn’t a lower-level reviewer call.
REMS Element Tiers: What Each One Adds
Not every REMS uses every tool the statute makes available. FDA scales the elements to the specific risk — see the REMS dictionary entry for the full operational definition of each element. In order of increasing restriction:
| Element | What it requires | When FDA adds it |
|---|---|---|
| Medication Guide / Patient Package Insert | FDA-approved, patient-facing information dispensed with the prescription. | Baseline tier — used when patient-directed information beyond standard labeling is the main gap. |
| Communication Plan | Manufacturer-distributed materials that alert prescribers, pharmacists, or other providers to the serious risk and REMS-specific requirements. | When the risk is manageable if providers are proactively informed, before they ever write the prescription. |
| Elements to Assure Safe Use (ETASU) | Prescriber certification/training, pharmacy or setting certification, restricted dispensing settings, mandatory patient monitoring or lab testing, and/or patient registry enrollment. | Reserved for the most severe risks, where labeling and communication alone can’t reliably prevent the harm — the statute requires ETASU to target one or more specific, named serious risks in the drug’s labeling, not general caution. |
| Implementation System | The operational infrastructure — often a shared, cross-manufacturer platform for a drug class — that actually monitors and enforces ETASU compliance. | Automatically required whenever a REMS includes ETASU; it isn’t optional once ETASU is in place. |
ETASU: What It Adds Beyond a Standard REMS
The distinction that trips people up: every ETASU-level REMS is a REMS, but most REMS never reach ETASU. A Medication Guide or Communication Plan relies on prescribers and patients voluntarily reading and acting on information. ETASU is structurally enforced — a pharmacy that isn’t certified in the REMS program cannot dispense the drug at all, regardless of whether the prescriber or patient wants it filled. That’s the functional difference between “informing” and “gatekeeping.”
A real, FDA-published example of how far ETASU-style restriction can go: the REMS for Zyprexa Relprevv (a long-acting injectable antipsychotic) exists specifically because the drug carries a risk of post-injection delirium/sedation syndrome — symptoms including sedation, confusion, or coma occurring within three hours of injection in a small percentage of cases. FDA’s REMS for the product restricts administration to certified health care facilities that can observe the patient for at least three hours after each injection and provide emergency care if the reaction occurs. The Medication Guide alone couldn’t accomplish that; only a setting restriction enforced through facility certification could. (Source: FDA, Risk Evaluation and Mitigation Strategies | REMS, fda.gov — content current as of May 2025, last verified for this page August 2026.)
Other long-running examples FDA and the research-compliance literature cite regularly: opioid analgesics with prescriber-education and patient-counseling elements, isotretinoin (historically administered under the iPLEDGE program) for its teratogenic risk, and clozapine for its risk of severe neutropenia. See the REMS dictionary term for how those map onto specific ETASU elements.
REMS Requirements Don’t End at Approval: The Assessment Timetable
A REMS isn’t a one-time filing. Under 21 U.S.C. § 355-1(d), the strategy must include a timetable of periodic assessments the manufacturer submits back to FDA:
| Milestone | Requirement |
|---|---|
| 18 months after initial approval | First required assessment of whether the REMS is achieving its goals. |
| 3 years after initial approval | Second required assessment. |
| 7 years after initial approval | Third required assessment. |
| Ongoing | Frequency can be increased or reduced by FDA as warranted, and the assessment requirement can be eliminated after the 3-year mark if FDA determines the drug’s serious risks are adequately identified, assessed, and managed. |
FDA can also require modifications to a REMS at any point if an assessment shows it isn’t meeting its stated safety goals — a REMS is a live compliance obligation, not a box checked once at launch.
What This Means for Clinical Research Sites
REMS requirements intersect with trial operations whenever a study uses an investigational drug that already carries — or is expected to carry — a REMS, or when a REMS-restricted approved drug is used as background or comparator therapy:
- Sites may need prescriber and/or pharmacy certification under the drug’s specific REMS program before they can dispense study drug — this is a separate compliance track from Good Clinical Practice training and from IRB approval, and it has its own lead time.
- Research pharmacies handling a REMS drug typically need to complete facility- or pharmacist-level certification with the drug’s implementation system before the investigational product can be dispensed on-site.
- Teams coordinating an Investigational New Drug (IND) application or an expanded access / compassionate use request for a REMS-restricted product should build REMS enrollment and certification into the study start-up timeline explicitly — it does not run on the same clock as IRB review and can become the rate-limiting step if it’s discovered late.
- A REMS negotiation is also one of the issues that can surface in an FDA Complete Response Letter if FDA and a sponsor haven’t aligned on the proposed strategy by the review action date.
Frequently Asked Questions
What are the actual REMS requirements a manufacturer has to meet?
At minimum: submitting the proposed strategy for FDA review and approval, implementing whichever elements FDA requires (Medication Guide, Communication Plan, ETASU, and/or an Implementation System), and meeting the periodic assessment timetable (18 months, 3 years, and 7 years after initial approval, per 21 U.S.C. § 355-1(d)). If FDA later determines the REMS isn’t meeting its goals, the manufacturer must also implement required modifications.
When is a REMS required, exactly?
When FDA determines — after weighing the six statutory factors above — that a REMS is necessary to ensure a drug’s benefits outweigh its risks. That can happen at initial approval or, later, if new safety information emerges about an already-marketed drug. It’s a case-by-case determination, not a fixed list of drug classes; most approved drugs do not have a REMS.
What is ETASU?
Elements to Assure Safe Use — the most restrictive tier a REMS can include. ETASU can require prescriber certification/training, pharmacy or care-setting certification, restricted dispensing locations, mandatory patient monitoring or lab testing, and/or patient registry enrollment, each targeted at mitigating one or more specific serious risks named in the drug’s labeling. Any REMS with ETASU must also include an Implementation System to monitor and enforce compliance.
What are the REMS elements, in order of how restrictive they are?
Medication Guide/Patient Package Insert (least restrictive — informational), Communication Plan (provider-directed outreach), Elements to Assure Safe Use / ETASU (structurally enforced restrictions), and Implementation System (the enforcement infrastructure required alongside ETASU). A given REMS can combine any subset of these; FDA does not require all four for every REMS.
Is a REMS the same as a boxed warning?
No — a boxed warning is part of standard FDA-approved labeling, while a REMS is a separate program with its own enforceable requirements layered on top of labeling. See the REMS dictionary entry for the full comparison.
Last verified August 2026 against 21 U.S.C. § 355-1 (Cornell Legal Information Institute, U.S. Code) and FDA’s Risk Evaluation and Mitigation Strategies | REMS overview page (fda.gov, content current as of May 20, 2025).
